References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21660
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654
- Teoh J, Hirai H W, Ho J, Chan F, Tsoi K, Ng C. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS One 2019; 14: e221775. doi: 10.1371/journal.pone.0221775
- Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin 2016; 66: 326-36. doi: 10.3322/caac.21333
- Ueno Y, Tamada T, Bist V, Reinhold C, Miyake H, Tanaka U, et al. Multiparametric magnetic resonance imaging: current role in prostate cancer management. Int J Urol 2016; 23: 550-7. doi: 10.1111/iju.13119
- Litjens G, Elliott R, Shih N, Feldman M, Kobus T, Kaa C, et al. Computer-extracted features can distinguish noncancerous confounding disease from prostatic adenocarcinoma at multiparametric MR imaging. Radiology 2016; 278: 135-45. doi: 10.1148/radiol.201514285
- Remmers S, Roobol M J. Personalized strategies in population screening for prostate cancer. Int J Cancer 2020; 147: 2977-87. doi: 10.1002/ijc.33045
- Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-57. doi: 10.1007/s00330-011-2377-y. 9
- Gupta RT, Mehta KA, Turkbey B, Verma S. PI-RADS: past, present, and future. J Magn Reson Imaging 2020; 52: 33-53. doi: 10.1002/jmri.26896
- Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 76: 340-51. doi: 10.1016/j.eururo.2019.02.033
- Gatti M, Faletti R, Calleris G, Giglio J, Berzovini C, Gentile F, et al. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radiol 2019; 44: 1883-93. doi: 10.1007/ s00261-019-01934-3
- Wassberg C, Akin O, Vargas HA, Dave AS, Zhang Jb, Hricak H. The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol 2012; 199: 360-6. doi: 10.2214/ AJR.11.6923
- Tamada T, Sone T, Jo Y, Hiratsuka J, Higaki A, Higashi H, et al. Locally recurrent prostate cancer after high- dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2- weighted imaging in localizing tumors. AJR Am J Roentgenol 2011; 197: 408-14. doi: 10.2214/AJR.10.5772
- Kuhl CK, Bruhn R, Krämer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 2017; 285: 493-505. doi: 10.1148/ radiol.2017170129
- Junker D, Steinkohl F, Fritz V, Bektic J, Tokas T, Aigner F, et al. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 2019; 37: 691-9. doi: 10.1007/s00345-018-2428-y
- Di Campli E, Delli P A, Seccia B, Cianci R, d’Annibale M, Colasante A, et al. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: comparison between readers with different experience. Eur J Radiol 2018; 101: 17-23. doi: 10.1016/j.ejrad.2018.01.028
- Huebner NA, Korn S, Resch I, Grubmüller B, Gross T, Gale R, et al. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media? Eur Radiol 2021; 31: 3754-64. doi: 10.1007/s00330-020-07494-1
- Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2017; 41: e1-7. doi: 10.1097/PAS.0000000000000820
- Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016; 69: 16-40. doi: 10.1016/j.eururo.2015.08.05
- Oishi M, Shin T, Ohe C, Nassiri N, Palmer SL, Aron M, et al. Which patients with negative magnetic resonance imaging can safely avoid biopsy for prostate cancer? J Urol 2019; 201: 268-76. doi: 10.1016/j.juro.2018.08.046
- Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2.1. J Magn Reson Imaging 2021; 53: 283-91. doi: 10.1002/jmri.27283
- Taghipour M, Ziaei A, Alessandrino F, Hassanzadeh E, Harisinghani M, Vangel M, et al. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdom Radiol 2019; 44: 1520-7. doi: 10.1007/s00261-018-1807-6
- Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-54. doi: 10.1148/ radiol.2291020200
- Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004; 91: 125- 50. doi: 10.1002/jcb.10772
- Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast- enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol 2012; 198: 1277-88. doi: 10.2214/ AJR.12.8510
- Sanz-Requena R, Martí-Bonmatí L, Pérez-Martínez R, García-Martí G. Dynamic contrast-enhanced case- control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness. Eur J Radiol 2016; 85: 2119-26. doi: 10.1016/j.ejrad.2016.09.022